Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia

• Conditions: Malignant Hematologic Disorder

• Registration Number: NCT02330718
• Lead Sponsor: Yonsei University

Brief Summary

The purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. This study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. Prospective cohort is for patients who are not in treatment for hematologic malignancy. Retrospective cohort is for patients who are diagnosed and in treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-12-29
• Study First Submitted QC: 2014-12-31
• Study First Posted: 2015-01-05
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-21
• Last Update Posted: 2019-02-22
• Primary Completion: 2019-12
• Study Completion: 2020-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• The patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 WHO classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy.
• Any gender and age ≥ 19 years
• Written informed consent
• Diagnosed after 2005-01-01 in retrospective cohort group.

Read More

Exclusion Criteria

• Patients who cannot understand or disagree the informed consent
• Patients who diagnosed with acute leukemia

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the number of patients with malignant hematologic disorders to examine the new prognostic factors and therapeutic targets	5 years

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of